Activity Agenda for IPA Cannabis Workshop

Hosted by: Patients Out of Time (Purchase Tickets by Clicking the Button to the Right)

Date: Thursday, 06/09/2022

Morning Session: 8:45AM-12:30PM

Location: Unity Temple | 707 W. 47th St., Kansas City, MO 64112

Patients Out of Time (P.O.T.) Pre-Conference Workshops include two separate educational accredited sessions the day prior to the main POT Conference. All coursework and presenters were specifically chosen by the POT founder, MaryLynn Mathre, who believes it is important to provide novice and beginning learners the basic foundations of cannabis therapeutics prior to the main conference. Coursework available for all levels of learners. Attendees must register, attend all coursework, take and pass the required tests and submit a completed survey in order to receive CMEs or certificates. 

*Attendees will need to register and pay for each Pre-Conference Workshop session separately. 

This course only Includes the morning IPA Pre-Conference Workshop and DOES NOT INCLUDE the afternoon P.O.T. Pre-Conference Workshop.

Morning Session: Integrative Providers Association (IPA) Cannabis Workshop hosted by Patents Out of Time will be both in-person and on-line coursework. This course will be viewing three (3) accredited courses from the IPAC2021NV Conference Series. IPA accredited coursework is packed full of information and insight regarding medical cannabis including an introduction to the IPA and will include the following courses: 1.) Cannabis: The Plant What Providers Need to Know | Evan DeZeeeuw, PharmD; 2.) Nourishing the ECS with Food, Nutrition & LIfestyle | Laura Lagano, MS, RND, CDN and; 3.) Cannabis and Substance Use Disorders: From a Gateway Drug to an Exit Modality | Mary Lynn Mathre, MSN, RN, CARN, Addiction Nursing. 

Accreditation: All IPA coursework approved and accredited for CMEs by the University of Nevada, Reno, School of Medicine, Office of Continuing Medical Education, an accredited provider of continuing medical education through the Accreditation Council for Continuing Medical Education (ACCME). 

Physicians: The University of Nevada, Reno School of Medicine designates this enduring material for a maximum of 3 AMA PRA Category 1 Credit(s)™.

Nurses: The University of Nevada, Reno School of Medicine approves this activity for 3 hours of nursing continuing education credit.

Certificate available for those seeking continuing education credits while all other licensed medical professionals may apply the coursework to their mandatory ongoing education requirements. Accredited coursework is available for ALL LICENSED HEALTHCARE PROVIDERS and levels of learners. Attendees must register, attend all coursework, take and pass the required tests and submit a completed survey in order to receive CMEs or certificates.

IPA Cannabis Coursework (3 CMEs): 

1. Cannabis: The Plant What Providers Need to Know | Evan DeZeeeuw, PharmD
2. Nourishing the ECS with Food, Nutrition & LIfestyle | Laura Lagano, MS, RND, CDN
3. Cannabis and Substance Use Disorders: From a Gateway Drug to an Exit Modality | Mary Lynn Mathre, MSN, RN, CARN, Addiction Nursing

Morning Session Schedule: 

8AM-9AM: Check-In/Registration (CME and Certificate Attendees) 

8:45AM-9AM: Introduction to IPA Hosted by: Patients Out of Time 

9AM-10AM: Cannabis: The Plant, What Providers Need to Know

10AM-10:10AM: Break

10:10AM-11:10AM: Nourishing the ECS with Food, Nutrition & Lifestyle

11:10AM - 12:10 PM:  Cannabis and Substance Use Disorders: From a Gateway Drug to an Exit Modality

12:10PM-12:30PM: Course Test and Evaluations  

(Purchase Tickets by Clicking the Button at the Top Right Under the Photos)

Disclosures:

Pt. 1 Speaker and Disclosures: Evan DeZeeuw, PharmD | None

Pt. 2 Speaker and Disclosures: Laura Lagano, MS, RDN, CDN | None

Pt. 3 Speaker and Disclosures: Mary-Lynn Mathre, MSN, RN, CARN | Director, Patients Out of Time

Planner Disclosures: Nurse Julie Monteiro | President, Integrative Providers Association and Compassion Center

IPA Course Overviews: 

Evan DeZeeuw, PharmD

Title: Cannabis: The Plant What Providers Need to Know

Overview: This course provides an overview of the current and relevant literature regarding Cannabis sativa L. in health and medicine. The plant will be discussed in its historical, botanical and medicinal context along with types of preparations, routes of administration and dosage forms. Discussion on patient barriers in today’s cannabinoid medicine landscape will be reviewed by Evan DeZeeuw, PharmD who has a passion for this medicinal plant and brings it to a simple understanding where learners leave with a greater understanding and appreciation of Cannabis sativa L. Cannabis: The Plant What Providers Need to Know is an excellent course for all providers needing an understanding on this medicinal plant.

Resources: 

• Chandra, S., Lata, H., & ElSohly, M. A. (Eds.). (2017). Cannabis sativa L.-botany and biotechnology. Springer.
• Damkier, P., Lassen, D., Christensen, M., Madsen, K. G., Hellfritzsch, M., & Pottegård, A. (2019). Interaction between warfarin and cannabis. Basic & clinical pharmacology & toxicology, 124(1), 28–31. https://doi.org/10.1111/bcpt.13152
• Decuyper, I. I., Rihs, H. P., Van Gasse, A. L., Elst, J., De Puysseleyr, L., Faber, M. A., Mertens, C., Hagendorens, M. M., Sabato, V., Bridts, C., De Clerck, L., & Ebo, D. G. (2019). Cannabis allergy: what the clinician needs to know in 2019. Expert review of clinical immunology, 15(6), 599–606. https://doi.org/10.1080/1744666X.2019.1600403
• De Petrocellis, L., Ligresti, A., Moriello, A. S., Allarà, M., Bisogno, T., Petrosino, S., Stott, C. G., & Di Marzo, V. (2011). Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes. British journal of pharmacology, 163(7), 1479–1494. https://doi.org/10.1111/j.1476-5381.2010.01166.x
• ElSohly, M. A., Mehmedic, Z., Foster, S., Gon, C., Chandra, S., & Church, J. C. (2016). Changes in Cannabis Potency Over the Last 2 Decades (1995-2014): Analysis of Current Data in the United States. Biological psychiatry, 79(7), 613–619. https://doi.org/10.1016/j.biopsych.2016.01.004 
• Falk, A. A., Hagberg, M. T., Löf, A. E., Wigaeus-Hjelm, E. M., & Wang, Z. P. (1990). Uptake, distribution and elimination of alpha-pinene in man after exposure by inhalation. Scandinavian journal of work, environment & health, 16(5), 372–378. https://doi.org/10.5271/sjweh.1771
• Gaston, T. E., Bebin, E. M., Cutter, G. R., Liu, Y., Szaflarski, J. P., & UAB CBD Program (2017). Interactions between cannabidiol and commonly used antiepileptic drugs. Epilepsia, 58(9), 1586–1592. https://doi.org/10.1111/epi.13852
• Komori, T., Fujiwara, R., Tanida, M., Nomura, J., & Yokoyama, M. M. (1995). Effects of citrus fragrance on immune function and depressive states. Neuroimmunomodulation, 2(3), 174–180. 
• Kumar S., Singh R., Kumar V., Rani A., Jain R. (2017) Cannabis sativa: A Plant Suitable for Phytoremediation and Bioenergy Production. In: Bauddh K., Singh B., Korstad J. (eds) Phytoremediation Potential of Bioenergy Plants. Springer, Singapore. https://doi.org/10.1007/978-981-10-3084-0_10

Laura Lagano, MS, RND, CDN

Title: Nourishing the ECS with Food, Nutrition and Lifestyle

Overview:  This presentation will explore nutrition and the importance of focusing on this modality in all healthcare practices in nourishing the Endocannabinoid System (ECS) with food, nutrition & other lifestyle habits. Course reviews the basic history of cannabis, designation between cannabis vs hemp, the components that make up cannabis and the basis of cell biology and cellular health. Without either, there is no life. Discussion covering cannabis researcher and neurologist Ethan Russo, who discovered that we all have a clinical endocannabinoid tone, reflected by our levels of endocannabinoids and the relative abundance and function of our endocannabinoid receptors. Because the ECS interacts with every other system of the body with the ultimate goal of balance and homeostasis, the ECS impacts overall health. To keep many of these systems operating at optimal states, various lifestyle habits are often modified or added. Essentially, by nourishing the ECS you are also changing the functioning of the ECS when you change lifestyle habits. This presentation will provide an overview of the habits that can impact the ECS and, ultimately, health status.

Resources: 

• The ECS Hyperphagia and Obesity. Physiol Behav. 171, 32-9, 2017 Mar 15; Donovan A Argueta, Nicholas V DiPatrizio, PMID: 28065722 PMCID: PMC5296283 DOI: 10.1016/physbeh.2016.12.004
• Peripheral endocannabinoid signaling controls hyperphagia in western diet-induced obesity https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5296283/ 
• The psychiatric side-effects of rimonabant. Brazilian Journal of Psychiatry, Rev. Bras. Pisquiatr. Vol.31 no.2 Sao Paulo June 2009. https://www.scielo.br/j/rbp/a/sBFrGRHXGfxHFmrjNvrNsHd/abstract/?lang=en  
• https://pubmed.ncbi.nlm.nih.gov/19578688/ 
• Targeting the endocannabinoid/CB1 receptor system for treating obesity in Prader-Willi syndrome https://pubmed.ncbi.nlm.nih.gov/27900261/ 
• Obesity and Cannabis Use: Results From 2 Representative National Surveys. https://pubmed.ncbi.nlm.nih.gov/21868374/ 
• Cannabis in Cancer Care. D.Abrams, M.Guzman. https://pubmed.ncbi.nlm.nih.gov/25777363/ 

Mary Lynn Mathre, MSN, RN, CARN 

Title: Cannabis and Substance Use Disorders: From a Gateway Drug to an Exit Modality

Overview: This course will include a general overview of the endocannabinoid system to provide the learner with a better understanding of how and why cannabis can serve as a therapeutic agent in dealing with substance use disorders.  Over the past decade, there has been an epidemic of opioid addiction and overdoses, along with continued problems associated with alcohol, tobacco and other substances of abuse.  Clinicians have been taught that cannabis is a gateway drug to more dangerous and addictive substances, which has been supported by the wrongful placement of cannabis in Schedule I of the Controlled Substances.  This course will provide a description of cannabis as a botanical medicine that contains numerous cannabinoids, terpenes and flavonoids that together can produce therapeutic effects based on the composition of the various chemovars.  Historical use, anecdotal reports and large population studies have shown that persons have been able to treat their substance use disorder with cannabis. Explains how cannabis can help mitigate withdrawal symptoms from drugs of abuse and can help treat substance use disorders.  Clinicians will be challenged to question the placement of cannabis in Schedule I and to improve their assessment skills in evaluating the use patterns of cannabis users to determine if use is therapeutic or if the patient has a cannabis use disorder.

Resources:

• Cannabis as a substitute for alcohol and other drugs. https://pubmed.ncbi.nlm.nih.gov/19958538/ 
• Medical cannabis access, use, and substitution for prescription opioids and other substances: A survey of authorized medical cannabis patients. https://pubmed.ncbi.nlm.nih.gov/28189912/ 
• Emerging Evidence for Cannabis' Role in Opioid Use Disorder. https://pubmed.ncbi.nlm.nih.gov/30221197/ 
• Impact of Cannabis Use During Stabilization on Methadone Maintenance Treatment. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4717827/ 
• Cannabidiol for the Reduction of Cue-Induced Craving and Anxiety in Drug-Abstinent Individuals With Heroin Use Disorder: A Double-Blind Randomized Placebo-Controlled Trial. https://pubmed.ncbi.nlm.nih.gov/31109198/ 
•  Intermittent marijuana use is associated with improved retention in naltrexone treatment for opiate-dependence. https://pubmed.ncbi.nlm.nih.gov/19444734/